November 2014 marks the 10th anniversary of the launch of Nature Reviews Clinical Oncology, originally published under the title of Nature Clinical Practice Oncology. To celebrate this milestone, we have commissioned a collection of Decade in Review articles from key opinion leaders to summarize the major advances in six sub-specialties of oncology over the past 10 years. We also present a comprehensive Perspectives article that summarizes the key advances and challenges in translational oncology. In addition, we have commissioned a Viewpoint article in which we asked four of our Advisory Board members from around the globe to discuss topics such as clinical development and testing of multiple agents in combination, regulatory challenges relating to drug development and trial design, and funding for basic research. Together, these articles provide an authoritative snapshot of the oncology field in 2014, and how this might progress over the forthcoming decade. These articles, together with a special infographic,provides a snapshot of 10 years of the journal in numbers.
EDITORIAL
Celebrating 10 years since launch
Lisa Hutchinson
doi:10.1038/nrclinonc.2014.164
Nature Reviews Clinical Oncology 11, 619 (2014)
NEWS & VIEWS
Decade in review—cancer immunotherapy: Entering the mainstream of cancer treatment
Steven A. Rosenberg
doi:10.1038/nrclinonc.2014.174
Nature Reviews Clinical Oncology 11, 630-632 (2014)
Decade in review—clinical trials: Shifting paradigms in cancer clinical trial design
Daniel J. Sargent & Edward L. Korn
doi:10.1038/nrclinonc.2014.167
Nature Reviews Clinical Oncology 11, 625-626 (2014)
Decade in review—targeted therapy: Successes, toxicities and challenges in solid tumours
Joel W. Neal & George W. Sledge
doi:10.1038/nrclinonc.2014.171
Nature Reviews Clinical Oncology 11, 627-628 (2014)
Decade in review—genomics: A decade of discovery in cancer genomics
Kenneth Offit
doi:10.1038/nrclinonc.2014.170
Nature Reviews Clinical Oncology 11, 632-634 (2014)
Decade in review—haematological cancer: Advances in biology and therapy
S. Vincent Rajkumar & Philippe Moreau
doi:10.1038/nrclinonc.2014.172
Nature Reviews Clinical Oncology 11, 628-630 (2014)
Decade in review—funding in cancer research: National Cancer Institute awards—a work in progress
Tito Fojo & Paraskevi Giannakakou
doi:10.1038/nrclinonc.2014.173
Nature Reviews Clinical Oncology 11, 634-636 (2014)
REVIEWS
Translational research in oncology—10 years of progress and future prospects
James H. Doroshow & Shivaani Kummar
doi:10.1038/nrclinonc.2014.158
Nature Reviews Clinical Oncology 11, 649-662 (2014)
The landscape of translational oncology has shifted dramatically over the past 10 years, characterized by the introduction of more-sophisticated molecular tools into the clinic and advances are being employed in genomic clinical trials that will examine the feasibility of matching a broad range of systemic therapies to specific molecular tumour characteristics. The authors review selected developments in translational cancer biology, diagnostics, and therapeutics that have occurred over the past decade and offer our thoughts on future prospects for the next few years.
PERSPECTIVES
Clinical cancer research: the past, present and the future
Vincent T. DeVita Jr, Alexander M. M. Eggermont, Samuel Hellman & David J. Kerr
doi:10.1038/nrclinonc.2014.153
Nature Reviews Clinical Oncology 11, 663-669 (2014)
In this Viewpoint, four of our Advisory Board members discuss the key challenges in clinical cancer research that need to be overcome to achieve tangible progress in the next decade. The issues and challenges include clinical development and testing of multiple agents in combination, design of clinical trials, tumour heterogeneity, drug development and trial design, and funding for cancer research. What have we learnt over the past 10 years and how should we progress in the next decade?
© 2018 Macmillan Publishers Limited, part of Springer Nature. All Rights Reserved.
